Geron

Geron Current Liabilities

The Current Liabilities of Geron (GERN) as of Oct 8, 2026 is 111.54 M USD. In the previous year, Current Liabilities was 146.48 M USD — a change of -23.85% (lower).

Current Liabilities

111.54 MUSD

YoY

-23.85%

Last updated:

Current Liabilities of Geron is 2025 111.54 M USD. Current Liabilities of Geron was 2024 146.48 M USD. It decreases by -23.85% lower compared to the previous year.

The Geron Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
11.55 M USD
Jan 1, 2019
40.86 M USD
Jan 1, 2020
54.94 M USD
Jan 1, 2021
84.32 M USD
Jan 1, 2022
143.19 M USD
Jan 1, 2023
209.98 M USD
Jan 1, 2024
146.48 M USD
Jan 1, 2025
111.54 M USD
The Geron Current Liabilities history
YEARCurrent LiabilitiesYoY
111.54 MUSD-23.85%
146.48 MUSD-30.24%
209.98 MUSD+46.64%
143.19 MUSD+69.82%
84.32 MUSD+53.48%
54.94 MUSD+34.45%
40.86 MUSD+253.75%
11.55 MUSD-7.71%
12.52 MUSD-19.09%
15.47 MUSD+17.78%
13.13 MUSD-28.42%
18.35 MUSD+33.41%
13.75 MUSD-44.65%
24.85 MUSD+4.21%
23.84 MUSD-58.98%
58.13 MUSD+311.18%
14.14 MUSD-4.03%
14.73 MUSD-40.83%
24.89 MUSD-55.53%
55.97 MUSD+282.63%
14.63 MUSD+9.32%
13.38 MUSD-25.24%
17.90 MUSD+11.58%
16.04 MUSD-9.61%
17.74 MUSD+24.75%
14.23 MUSD-1.90%
14.50 MUSD+154.39%
5.70 MUSD0.00%
5.70 MUSD-10.94%
6.40 MUSD+68.42%
3.80 MUSD+123.53%
1.70 MUSD—
Access this data via the Eulerpool API

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

Current Liabilities of Geron is 111.54 M USD in 2025.

Current Liabilities of Geron changed from 146.48 M USD to 111.54 M USD, representing a -23.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Geron since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Geron historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Geron

All Key Metrics — Geron